‘Development of autism treatment’ Neuroventi participates in ‘World Autism Day’ campaign

23-03-31

Neuroventi (CEO Shin Chan-young), an autism treatment development company, announced on the 31st that it participated in the 'World Autism Day' (April 2 every year) campaign.

'World Autism Day' is an anniversary designated by the United Nations (UN) to raise social awareness of autism. To commemorate this day, the 'Light It Up Blue' campaign will be held to light up blue lights at landmarks in 170 countries around the world. Blue symbolizes understanding and hope, and is known to be the most comfortable color for people with autism.

Neuroventi also joined the campaign to commemorate 'World Autism Day' by unifying executives and staff at the head office and research center in blue clothes. Through this, the company explained that it has strengthened its will to develop a treatment so that people with autism can lead full and meaningful lives.

Neuroventi is a company developing a precision complex targeting autism treatment that selectively binds to neurotransmitter receptors closely related to sociality. The company's autism treatment candidate has proven its sociality improvement effect in a number of genetic and environmental autism animal models. Neuroventi is preparing to enter phase 2 clinical trials in 2023.

An official from Neuroventi said, "In addition to developing therapeutic agents, we have established various central nervous system animal disease models and efficacy evaluation analysis platforms such as autism, ADHD, depression, dementia, Parkinson's disease, schizophrenia, and epilepsy." The CDRO project for central nervous system efficacy evaluation and side effect verification is also cruising.”